SRRK

Scholar Rock Holding Corp

SRRK, USA

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

https://www.scholarrock.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SRRK
stock
SRRK

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Read more →
SRRK
stock
SRRK

Bellevue Group AG Boosts Holdings in Scholar Rock Holding Corporation $SRRK MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$47.3333

Analyst Picks

Strong Buy

6

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

21.76

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-41.72 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-24.83 %

Low 2%

High 10%

Debt to Equity

-

Medium

0.68

Low 1

High 0.3

Investors

* Institutions hold a combined 122.93% of the total shares of Scholar Rock Holding Corp

1.

FMR Inc

(14.3922%)

since

2025/06/30

2.

Siren, L.L.C.

(9.6227%)

since

2025/06/30

3.

T. Rowe Price Associates, Inc.

(9.1146%)

since

2025/06/30

4.

BlackRock Inc

(6.9656%)

since

2025/06/30

5.

Samsara BioCapital, LLC

(5.839%)

since

2025/06/30

6.

Fidelity Growth Compy Commingled Pl S

(5.0587%)

since

2025/07/31

7.

Vanguard Group Inc

(5.0575%)

since

2025/06/30

8.

Redmile Group, LLC

(4.0873%)

since

2025/06/30

9.

US Small-Cap Growth II Equity Comp

(3.7182%)

since

2025/06/30

10.

Fidelity Growth Company Fund

(3.6209%)

since

2025/07/31

11.

T. Rowe Price New Horizons

(3.4068%)

since

2025/07/31

12.

State Street Corp

(3.1982%)

since

2025/06/30

13.

Bellevue Group AG

(3.066%)

since

2025/06/30

14.

Eventide Asset Management, LLC

(3.0306%)

since

2025/06/30

15.

Vanguard Total Stock Mkt Idx Inv

(2.6789%)

since

2025/07/31

16.

BB Biotech AG Ord

(2.5869%)

since

2024/12/31

17.

HHG PLC

(2.549%)

since

2025/06/30

18.

Wellington Management Company LLP

(2.1064%)

since

2025/06/30

19.

Hood River Capital Management LLC

(2.0545%)

since

2025/06/30

20.

iShares Russell 2000 ETF

(2.0374%)

since

2025/08/31

21.

T. Rowe Price Health Sciences

(2.0224%)

since

2025/07/31

22.

Geode Capital Management, LLC

(1.9634%)

since

2025/06/30

23.

Fairmount Funds Management LLC

(1.8975%)

since

2025/06/30

24.

Marshall Wace Asset Management Ltd

(1.7065%)

since

2025/06/30

25.

Fidelity Select Biotechnology

(1.6984%)

since

2025/07/31

26.

Paradigm Biocapital Advisors LP

(1.665%)

since

2025/06/30

27.

Vestal Point Capital LP

(1.5604%)

since

2025/06/30

28.

Polar Capital Holdings PLC

(1.5604%)

since

2025/06/30

29.

Polar Capital Biotech S Inc

(1.5604%)

since

2025/07/31

30.

Eventide Gilead N

(1.5198%)

since

2025/06/30

31.

COMMODORE CAPITAL LP

(1.5084%)

since

2025/06/30

32.

Eventide Healthcare & Life Sciences I

(1.4975%)

since

2025/06/30

33.

SPDR® S&P Biotech ETF

(1.2681%)

since

2025/08/31

34.

T. Rowe Price New Horizons Tr-A

(1.2117%)

since

2025/06/30

35.

American Funds SMALLCAP World A

(1.1742%)

since

2025/06/30

36.

Fidelity Growth Company K6

(1.1499%)

since

2025/07/31

37.

Hood River Small-Cap Growth Instl

(1.1137%)

since

2025/06/30

38.

Fidelity Series Growth Company

(0.9715%)

since

2025/07/31

39.

Fidelity Small Cap Index

(0.8468%)

since

2025/06/30

40.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8379%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.9

EPS Estimate

-0.8458

EPS Difference

-0.0542

Surprise Percent

-6.4081%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.